A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

Registration-Inclusion Criteria for FAMILIAL PANCREATIC CANCER (FPC) and those with a BRCA1, BRCA2, LYNCH SYNDROME, ATM, PALB2, CDKN2A, or related gene mutation (one of the following is required for questions 1-3) 1. For FPC: The individual has at least 2 first-degree relatives (FDR) with PC. 2. For FPC: The individual has at least 3 first-, second-, or third-degree relatives with PC with at least 1 PC in a FDR. 3. The individual is a known mutation carrier of BRCA1, BRCA2, MLH1, MSH2, MSH6, or PMS2, ATM, PALB2, CDKN2A, or similar high-risk gene mutation and has at least 1 first- or second-degree relative with PC. 4. The individual is at least 50 years old or 10 years younger than the youngest relative with PC. 5. ECOG Performance Status of 0-1. 6. No known contraindications to MRI examination or gadolinium contrast. 7. Willing to undergo MRI and screening for metal implants or metal injury. 8. Estimated GFR \>29 mL/min 9. Ability to provide informed consent. 10. Willing to return to study site for all study assessments. Registration-Exclusion Criteria: 1. Prior history of pancreatic cancer. 2. Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years. 3. Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years). 4. Hereditary pancreatitis. 5. eGFR \< 30 mL/min 6. Contraindication to MRI examination or gadolinium contrast. 7. Pregnant or nursing women. 8. Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.